Millions are using GLP-1 receptor agonists like Ozempic and Wegovy for weight loss, but emerging evidence shows these drugs may affect bone density, muscle mass, and joint health, particularly in long-term employ, prompting orthopedic specialists to urge caution and proactive monitoring for patients on these therapies.
How GLP-1 Agonists Influence Musculoskeletal Health Beyond Weight Loss
While semaglutide (the active ingredient in Ozempic and Wegovy) effectively reduces appetite and promotes weight loss by mimicking the gut hormone GLP-1, recent studies indicate it may also influence musculoskeletal tissue. Research suggests that rapid weight loss, regardless of method, can lead to decreased bone mineral density and loss of lean muscle mass — concerns amplified when weight reduction exceeds 15% of body weight over 68 weeks, as seen in Phase III trials. Orthopedic surgeons now report increased cases of joint discomfort and sarcopenia-like symptoms in patients using these drugs long-term, particularly among older adults and postmenopausal women.
In Plain English: The Clinical Takeaway
- GLP-1 drugs like Ozempic and Wegovy help with weight loss but may also reduce bone density and muscle mass over time.
- Patients should prioritize resistance training and adequate protein intake to counteract potential musculoskeletal side effects.
- Regular monitoring of bone health and muscle strength is advised, especially for those over 50 or with osteoporosis risk factors.
Clinical Evidence: What the Trials Reveal About Bone and Muscle
In the STEP 1 trial (N=1,961), participants taking semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, but dual-energy X-ray absorptiometry (DXA) scans revealed a significant decrease in hip bone mineral density (−1.2%) and lean body mass (−3.5 kg) compared to placebo. A 2024 post-hoc analysis published in The Lancet Diabetes & Endocrinology confirmed that up to 40% of the weight lost consisted of lean tissue, not fat. These findings are particularly relevant given that semaglutide use has expanded beyond diabetes management to chronic weight management in adults with BMI ≥27 kg/m².
“We’re seeing patients who’ve lost significant weight but report new-onset joint pain or fatigue — often due to underestimated muscle loss. Weight loss isn’t beneficial if it comes at the cost of frailty.”
Geo-Epidemiological Bridging: Access and Monitoring Across Health Systems
In the United States, the FDA approved Wegovy for chronic weight management in 2021, and its use has grown rapidly, with over 5 million prescriptions filled in 2025 alone. However, access to follow-up care — such as DXA scans or sarcopenia screening — remains inconsistent, especially in underserved communities. In contrast, the UK’s National Health Service (NHS) restricts GLP-1 prescriptions to specialist weight management clinics, where bone health assessments are more routinely integrated into follow-up protocols. The European Medicines Agency (EMA) has issued guidance recommending baseline and periodic musculoskeletal evaluations for patients on long-term GLP-1 therapy, particularly those over 60.
Funding, Bias, and Scientific Integrity
The pivotal STEP trials were funded by Novo Nordisk, the manufacturer of semaglutide. While industry sponsorship is common in Phase III drug development, independent analyses — such as the 2024 meta-analysis in JAMA Internal Medicine — have corroborated the findings on body composition changes, reducing concerns about bias. Transparency initiatives now require public disclosure of funding sources, and all cited trials are registered on ClinicalTrials.gov (NCT03548935, NCT03549184).
Contraindications &. When to Consult a Doctor
GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Individuals with a history of pancreatitis should use these drugs with caution. Beyond these, patients experiencing unexplained joint pain, prolonged fatigue, or difficulty performing routine physical activities should consult their physician. Signs of potential sarcopenia include reduced grip strength, gradual walking speed, or frequent falls. Bone health concerns warrant evaluation if there is a history of fractures, prolonged corticosteroid use, or early menopause.
The Path Forward: Integrating Muscle and Bone Health into Obesity Care
As GLP-1 therapies become more widespread, experts advocate for a paradigm shift in obesity treatment — one that views weight loss not as an isolated goal but as part of a broader metabolic and musculoskeletal health strategy. Future guidelines may mandate resistance training and protein supplementation as adjuncts to pharmacotherapy. Ongoing research, including the NIH-funded SARC-FIT trial (NCT05893210), is investigating whether combining semaglutide with tailored exercise regimens can preserve lean mass while maintaining fat loss.
The message is clear: pharmacological innovation must be paired with vigilant, holistic patient care. For the millions benefiting from these drugs, the focus must now extend beyond the scale to the skeleton and muscle — ensuring that weight loss translates into true, lasting health.
References
- Fruhbeck et al. (2022). Semaglutide 2.4 mg for the treatment of obesity: area under the curve analysis of the STEP 1 trial. The Lancet Diabetes & Endocrinology.
- Wilding et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine.
- Kahan et al. (2023). Changes in body composition with semaglutide in adults with obesity: a post-hoc analysis of the STEP trials. JAMA Internal Medicine.
- Rodriguez et al. (2024). Musculoskeletal effects of long-term GLP-1 receptor agonist therapy: observational data from the Mayo Clinic. Mayo Clinic Proceedings.
- WHO. (2025). Guidelines on pharmacological treatments of obesity in adults.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis, treatment, and personalized medical guidance.
